Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hims & Hers Health’s rise from start-up to public telehealth leader is powered by one metric investors can’t ignore: subscriber retention across dermatology, mental-health and primary-care lines. That data lives deep inside each SEC filing.
Stock Titan surfaces exactly what matters. Our AI engine turns the dense language of a Hims & Hers Health annual report 10-K simplified into plain-English insights on fulfillment margins, privacy compliance costs and segment revenue. Need the latest Hims & Hers Health quarterly earnings report 10-Q filing? It arrives here in real time, alongside concise commentary that links prescription growth to cash-flow swings. Material developments—regulatory shifts, pharmacy partnerships, class-action updates—trigger a Hims & Hers Health 8-K material events explained snapshot within minutes.
Want to monitor management moves? Our alerts flag every Hims & Hers Health Form 4 insider transactions real-time so you can compare option exercises against marketing-spend disclosures. The page also answers common searches such as “Hims & Hers Health insider trading Form 4 transactions” and “Hims & Hers Health proxy statement executive compensation,” pairing raw documents with readable summaries.
- AI-powered digests that make understanding Hims & Hers Health SEC documents with AI straightforward
- Cross-links to Hims & Hers Health earnings report filing analysis for trend tracking
- Downloadable exhibits covering Hims & Hers Health executive stock transactions Form 4
Stop wading through 300 pages; let Stock Titan transform complex disclosures into investable clarity.
Hims & Hers Health, Inc. disclosed that director Schultz Kare was granted 3,656 restricted stock units (RSUs), each representing a contingent right to receive one share of Class A common stock. The RSUs vest subject to continuous service on the earlier of the company’s 2026 annual meeting or June 15, 2026, and will convert into 3,656 Class A shares upon vesting. The report shows the award is held in direct form and reflects equity-based, time‑based compensation for a board member rather than a cash transaction or sale. Without information on total outstanding shares, the absolute size of this grant limits assessment of materiality, but the filing documents a routine director equity award and alignment of the director’s interests with long‑term shareholder value.
Pendarvis Christiane, a director of Hims & Hers Health, Inc. (HIMS), was granted 3,656 Restricted Stock Units (RSUs) on 08/06/2025. Each RSU represents a contingent right to receive one share of Class A common stock at no cash price, and the award is recorded as a direct ownership interest of 3,656 shares following the grant.
The RSUs vest subject to continuous service on the earlier of the company’s 2026 annual meeting of stockholders or June 15, 2026, meaning the award is intended to align the director’s incentives with shareholder outcomes over the coming year.
Hims & Hers Health, Inc. (HIMS) – Form 144 filing: An unnamed insider has notified the SEC of a proposed sale of 60,000 Class A shares, representing roughly 0.03 % of the 217.6 million shares outstanding. The shares have an aggregate market value of $3,214,880.58 and are expected to be sold on or about 08/06/2025 through the NYSE using Fidelity Brokerage Services.
The shares derive from two equity-compensation events:
- 39,721 shares acquired on 02/28/2022 via a stock-option exercise paid in cash.
- 20,279 shares vested on 06/15/2025 as restricted-stock compensation.
This filing signals an intended discretionary liquidation by a company affiliate; while small relative to total float, it may be interpreted by investors as a modest insider-sentiment data point.
Hims & Hers Health, Inc. (HIMS) – Form 144 filing discloses an insider’s intention to sell 250 Class A shares (estimated market value $16,110) on or after 1 Aug 2025 through Fidelity Brokerage on the NYSE. The notice also details recent insider activity: over the past three months the same individual, Michael Y. Chi, has already sold 69,802 Class A shares for gross proceeds of ≈$4.27 million. Outstanding Class A shares total 215.45 million, so the planned sale represents a negligible 0.0001% of shares outstanding, while the cumulative three-month sales equal roughly 0.03%.
The signer affirms he is unaware of any undisclosed material adverse information and, if relying on Rule 10b5-1, that a compliant trading plan exists. No other financial metrics, guidance, or operational updates are provided; the filing is strictly a procedural notice under Rule 144.
Hims & Hers Health, Inc. (HIMS) – Form 144 filing
Insider Michael Y. Chi has filed a notice to sell 26,350 Class A shares through Fidelity Brokerage on or about 31 Jul 2025 on the NYSE. At the 07/30/25 market price used by the filer, the stake is valued at $1.77 million and represents roughly 0.012 % of the company’s 215.45 million shares outstanding.
The shares were acquired via four employee option grants dated 24 Feb 2022, 27 May 2021, 10 Aug 2022 and 01 Mar 2023, all exercised for cash on 31 Jul 2025. Over the past three months Chi has already disposed of 43,452 shares in five open-market transactions between 06 Jun 2025 and 24 Jul 2025, generating $2.51 million in gross proceeds.
No additional financial data, earnings guidance or company commentary is included in this notice. The filing merely discloses the planned sale under Rule 144 and affirms that the filer is not in possession of undisclosed material adverse information.
Hims & Hers Health, Inc. (HIMS) filed a Form 144 indicating that stockholder Soleil Boughton intends to sell 2,572 Class A shares through Fidelity Brokerage on or about 07/28/2025 on the NYSE. The proposed sale has an aggregate market value of $150,976.40, based on data supplied in the filing. Shares outstanding are listed at 215,453,899, so the contemplated sale represents roughly 0.0012 % of total Class A shares.
The shares to be sold were acquired via restricted-stock vesting on 06/15/2025 and are being sold for compensation purposes. The filer certifies possession of no undisclosed material adverse information.
Recent activity: Over the past three months, the same seller disposed of 22,871 shares across seven transactions, generating $1.18 million in gross proceeds. Transaction sizes ranged from 2,572 to 5,451 shares, signalling a pattern of periodic liquidations rather than a single block sale.
No other financial metrics, earnings data, or company-level events are disclosed in this notice.
FAQ
What is the current stock price of Hims & Hers Health (HIMS)?
What is the market cap of Hims & Hers Health (HIMS)?
